About this Research Topic
Bone metabolism is a fundamental biological mechanism involved in bone formation and directly affects bone development. Osteoclasts and osteoblasts play pivotal roles in bone resorption (breakdown) and bone formation, respectively. Numerous bone diseases exhibit abnormal osteoclast activity, leading to bone deformities and significant functional impairment. Common bone disorders like osteoporosis and neoplastic bone diseases are characterized by increased bone resorption, resulting in reduced bone mass, damage to the internal ultrastructure, and a heightened risk of bone fragility and fractures. RNA editing and metabolism have been identified as critical factors in this process. Despite the use of various anti-absorption drugs to inhibit bone loss, their effectiveness remains unsatisfactory due to off-target effects and potential side effects. Additionally, the duration of their effects is usually short, with discontinuation often resulting in rapid bone loss and an increased fracture risk. Therefore, it is crucial in clinical practice to explore new therapeutic targets for these conditions.
Recent advances in understanding RNA metabolism abnormalities provide significant research evidence for their diagnostic and therapeutic potential in various bone metabolic diseases. These conditions include bone tumors, osteoporosis, bone immune diseases, neurological diseases, and osteosclerosis.
Our research aims to comprehensively and critically understand the mechanisms and preclinical studies of RNA metabolic abnormalities in the pathophysiology of bone metabolic diseases. We also seek to assess their potential for diagnosing and treating these conditions, while reviewing the latest advancements in this field. The publication of our research articles will contribute to gaining new insights into the epigenetic mechanisms involved in RNA synthesis, editing, and degradation in the etiology of bone metabolic diseases. Specific topics that are of interest included, but are not limited to:
• Mechanisms of RNA metabolism in age-related or hormone-related osteoporosis.
• Application of nano-complexes that regulate RNA metabolism in the treatment of bone defects.
• Regulation of RNA metabolism through physical stimuli (such as pressure or temperature) or chemical stimuli (such as bioactive proteins or peptides) for the treatment of bone resorption disorders.
• Application of immune-based and RNA-regulatory drugs in the treatment of abnormal bone resorption diseases.
• Regulation and treatment of RNA metabolism in bone destruction caused by bone tumors.
• The regulatory effects of RNA metabolism on the coupling of osteoblasts and osteoclasts.
• Epidemiological characteristics and analysis of risk factors for diseases associated with abnormal bone resorption.
• The role of anti-osteoporosis drugs in regulating cell proliferation, differentiation, and oxidative stress.
• The potential benefits of monitoring RNA metabolism in the prevention of osteoporosis-related diseases.
• Novel treatment strategies targeting RNA metabolism for estrogen deficiency and inflammatory osteoporosis.
Recent advances in understanding RNA metabolism abnormalities provide significant research evidence for their diagnostic and therapeutic potential in various bone metabolic diseases. These conditions include bone tumors, osteoporosis, bone immune diseases, neurological diseases, and osteosclerosis.
Our research aims to comprehensively and critically understand the mechanisms and preclinical studies of RNA metabolic abnormalities in the pathophysiology of bone metabolic diseases. We also seek to assess their potential for diagnosing and treating these conditions, while reviewing the latest advancements in this field. The publication of our research articles will contribute to gaining new insights into the epigenetic mechanisms involved in RNA synthesis, editing, and degradation in the etiology of bone metabolic diseases. Specific topics that are of interest included, but are not limited to:
• Mechanisms of RNA metabolism in age-related or hormone-related osteoporosis.
• Application of nano-complexes that regulate RNA metabolism in the treatment of bone defects.
• Regulation of RNA metabolism through physical stimuli (such as pressure or temperature) or chemical stimuli (such as bioactive proteins or peptides) for the treatment of bone resorption disorders.
• Application of immune-based and RNA-regulatory drugs in the treatment of abnormal bone resorption diseases.
• Regulation and treatment of RNA metabolism in bone destruction caused by bone tumors.
• The regulatory effects of RNA metabolism on the coupling of osteoblasts and osteoclasts.
• Epidemiological characteristics and analysis of risk factors for diseases associated with abnormal bone resorption.
• The role of anti-osteoporosis drugs in regulating cell proliferation, differentiation, and oxidative stress.
• The potential benefits of monitoring RNA metabolism in the prevention of osteoporosis-related diseases.
• Novel treatment strategies targeting RNA metabolism for estrogen deficiency and inflammatory osteoporosis.
Keywords: Bone metabolic diseases, osteoblast, osteoclast, RNA metabolism
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
